Melanoma-associated antigens have been used to generate vaccines able of evoking an immune response against canine OMM, specifically tyrosinase (24–28, 57) and chondroitin sulfate proteoglycan 4 (CSPG4) (2, 3, 29–31). The gene discussed is CSPG4; the disease is melanoma.